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Abstract 
In general, metastatic renal cell carcinoma (mRCC) is managed with systemic treatments and 
cytoreductive nephrectomy is recommended only when it is feasible. Historically, systemic 
treatment of mRCC was limited to cytokine treatment with interferon (IFN) and interleukin 
(IL)-2, as chemotherapy was considered to be ineffective in these patients. Bevacizumab in 
combination with interferon alfa is approved for treatment-nave advanced renal cell carcinoma 
(RCC) in both the US and Europe. Its objective response rates is 30%. We report a case of a 
patient who presents a complete response after a nephrectomy and bevacizumab associated to 
interferon alpha.  
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Introduction  
Metastatic renal cell carcinoma (mRCC) has showed a resistance to chemotherapy and modest 
response to cytokine therapy [1]. Before the year 2000, high-dose interleukin-2 was the only drug that 
was approved by the U.S. Food and Drug Administration (FDA) for metastatic situation, with 10% 
longer duration of complete remission [2]. Interferon (IFN)-regimens have been used to treat 
metastatic RCC based on a survival advantage demonstrated in some studies [3].  
 The most common histologic variant, involving von Hippel-Lindau (VHL) tumor suppressor 
gene inactivation, has occurred. Normally VHL encodes a protein that is a component of a ligase for 
hypoxia-inducible factor (HIF). Under normal oxygen tension, ligase action inactivates HIF. Under 
hypoxic conditions, or with VHL inactivation, HIF upregulates the transcription of multiple hypoxia-
inducible genes, including those encoding vascular endothelial growth factor (VEGF), platelet-derived 
growth factor (PDGF), epidermal growth factor receptor (EGFR), transforming growth factor-, and 
others that promote angiogenesis and cellular proliferation [4]. Other non-VHL pathways leading to 
RCC may share aberrant activation of the hypoxic response.  
 Approved therapies include inhibitors of VEGF and PDGF receptors (sunitinib and 
sorafenib) and mammalian target of rapamycin (mTOR) inhibitors (temsirolimus and everolimus) [5]. 
Most recently, the anti-VEGF antibody bevacizumab in combination with IFN was approved and is 
the subject of this case report.  
Case Presentation  
A 64 years old male presented with cough and chest pain, the pulmonary radiography revealed nodules 
and a computed tomography scan (CT scan) showed a voluminous renal tumor with pulmonary 
metastases and a cytoreductive nephrectomy was performed in August 2011 and pathology revealed a 
Fuhrman grade 3 clear cell adenocarcinoma of 9x8x7 cm with necrosis (Figure 1), a cerebral scan 
revealed 2 metastases (Figure 2).  
 
  
 
Figure 1 CT scan showed pulmonary metastases   
 
 
Figure 2 a cerebral scan revealed 2 metastases 
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 After nephrectomy a signiﬁcant pulmonary response is observed (Figure 3). Stereotaxic 
encephalic radiotherapy is done in October 2011with a signiﬁcant control. Bevacizumab and interferon 
was started in November 2011 to April 2012 in the total of 12 cycles A complete response mediastino-
pulmonary is observed in January and cerebral complete response in March 2012. In January 2012 
interferon was stopped for toxicity asthenia grade 3 and in April 2012 bevacizumab was also stopped 
because the patient presented a heart failure with ejection fraction (EF: 48%) and a pulmonary arterial 
hypertension (PAH: 55+10mmHg) and decision was monitoring the patient every three months. The 
different CT scan and magnetic resonance imaging (MRI) conﬁrmed the control of the metastatic 
disease (Figure 4). In June 2016 a modification of cerebral metastases was observed in favour of a late 
necrosis induced by the radiotherapy and that was treated with corticoids and anti-epileptic. The most 
recent CT scan and MRI revealed a persistence of the complete response with almost six years without 
any specific treatment of the cancer. 
  
 
  
 
Figure 3. a CT scan showed a signiﬁcant pulmonary 
response 
 Figure 4. a CT scan and MRI conﬁrmed the 
control of the metastatic disease  
Discussion  
The treatment of metastatic renal cell carcinoma (mRCC) has been developed in the objective of 
transforming cancer to a chronic rather than a lethal disease. This has been demonstrated with the 
advances in systemic therapy. mRCC is known to have low response rates to classic cytotoxic therapy, 
with more than 70 agents had been tested and response rates is under 10% [6]. The American Cancer 
Society stated kidney cancer comprises approximately 3-5% of adult malignancies in the United States 
with approximately 61,000 new cases diagnosed and over 13,000 deaths reported in 2011[7]. 25% to 
30% of patients will present in metastatic stage and 25% to 30% are initially presented with localized 
disease will progress at sometimes [8].  
 The treatment of RCC consists on nephrectomy if localized case and medical treatment in the 
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metastatic case, a study showed that nephrectomy before interferon alfa-2b therapy for metastatic 
renal-cell cancer had a survival beneﬁt. Metastatic renal-cell cancer is very diﬃcult to treat effectively, 
because of its resistance to chemotherapy. Yagoda et al. reviewed a large series of trials of 
chemotherapeutic regimens and found a 5.6% rate of objective response to cytotoxic agents in 3502 
treated patients [6]. There are, also, indications of improved survival with chemotherapy after 
nephrectomy [5], previous trials of biologic-response modiﬁers in metastatic renal-cell cancer have 
shown an improved response rate or improved survival after surgery of the primary tumor [3]. The 
interval from nephrectomy to the systemic treatment of the renal-cell cancer was not controlled in 
these series. The effect of nephrectomy may, however, be real. Several reports of immunotherapy for 
renal-cell cancer, with or without concomitant chemotherapy, have supported the idea that patients 
who undergo nephrectomy before systemic treatment have a survival advantage [8].  
 The CARMENA trial, phase 3, multicenter and randomized, started in 2009. Initiated by the 
French Association of Urology and the Getug (Study Group of Urogenital Tumors), it was piloted at 
the Institute of Gustave Roussy (Villejuif). A total of 450 patients were included in this trial. They 
were treated either by surgery then sunitinib, or by sunitinib alone. After a follow-up of approximately 
4 years (51 months), overall survival was greater (more than 6 months) in the group treated with 
sunitinib alone than in the surgery. So in practice it will be possible to offer only and faster medical 
treatment for patients with metastatic tumors.  
 The place of palliative nephrectomy in monotherapy has been shown to be limited at present. 
Patients who present a poor condition, the surgery may lead to signiﬁcant morbidity and mortality [9]. 
The indication for palliative surgery should be set in a symptomatic patient when the primary tumor is 
considered potentially unresectable and usual measures are insuﬃcient to control the symptomatology 
[10]. In fact, palliative nephrectomy may not solve the speciﬁc problem which it was intended to 
palliate, given that the systemic effects may be caused by the metastatic diffusion rather than the 
primary tumor [7]. The QoL provided by palliative nephrectomy in selected patients may be seen im-
proved when compared with other alternative strategies [8]. The combination of bevacizumab and 
interferon alfa is now approved for treatment-nave advanced renal cell carcinoma (RCC) in both the 
US and Europe. Its objective response rates of 30% and progression-free survival rates of 910 months 
are comparable to the other approved ﬁrst-line multityrosine kinase inhibitors, sunitinib and pazopanib 
[10]. Bevacizumab (Avastin) is a humanized mAb that inhibits VEGF activity. It has signiﬁcant 
clinical beneﬁts in patients with the most common solid tumors, including metastatic colorectal 
carcinoma, metastatic breast cancer and non-small-cell lung carcinoma. Phase II trials demonstrated 
that bevacizumab has a moderate activity and is well tolerated in both groups patients therapy-naive 
and pre-treated mRCC[10]. Also, experience from clinical trials indicates that bevacizumab does not 
increase the toxicity of concomitantly administered chemotherapy [9]. Bevacizumab and IFN suppress 
tumor growth by direct and indirect mechanisms, and these two agents may have synergistic effects 
when are associated. Both agents have stimulatory effects on the immune response. For example, 
VEGF blockade, similarly to IFN treatment, has been shown to improve the function of dendritic cells 
[11], which is suppressed in advanced cancer as a result of VEGF-mediated inhibition [10]. Preclinical 
evidence also indicates that IFN has antiangiogenic activity [12] that is both dose and schedule 
dependent, with lower doses having greater antiangiogenic effects than 5-to 10-fold higher doses [9]. 
Until the middle of this past decade, immunotherapy with interleukin-2 (IL-2) or interferon-(IFN-) was 
considered to be the standard of care for mRCC. Response rates with high-dose IL-2 have been 
reported at 20%, and complete responses at 7% with a minority of patients achieving a durable 
response [13]. The toxicity proﬁle of the association often limits its indication [14]. Most patients 
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receive a dose of 918 MIU (subcutaneous) , three times per week, but this regimen is associated with 
important toxicity, most frequently fatigue and inﬂuenza-like symptoms, also depression and asthenia 
[12]. Some side-effects (depression) are not dose related, several studies have demonstrated that IFN 
dose reduction leads to improve overall tolerability for patients with hepatitis C and mRCC[15]. This 
prospective randomized trial showed a greater OS in patients with metastatic clear cell RCC receiving 
bevacizumab plus IFN-as initial systemic therapy compared with IFN-alone. However, the clinical 
beneﬁt of the addition of bevacizumab to IFN-is evident with prolonged PFS and increased objective 
response rate, as reported previously in this trial and in a similar phase III trial [10]. For patients with 
cerebral metastases there is an indication of stereotaxic radiotherapy especially for small tumors 
having size under 2 or 3cm with a signiﬁcant control. And expected patient survival may be used to 
guide clinicians about proper treatment strategy . Generally patients with an expected median survival 
under 3 months should not be exposed to potential risks of surgery or stereotactic radiotherapy since 
the cost/beneﬁt ratio of these treatment modalities is questionable in this group of patients.  
 The immune system to improve the prognosis for metastatic RCC has led to evaluation of 
several immune checkpoint inhibitors and vaccination strategies in multiple ongoing trials. The OS 
reported with the PD-1 inhibitor nivolumab in previously treated mRCC has already exceeded the 
median OS reported with IL2 in the ﬁrst-line treatment of mRCC with manageable toxicities. Com-
binations of PD 1 inhibition with VEGF-TKIs and CTLA-4 inhibitors have shown signiﬁcantly higher 
response rates. Meaningful clinical beneﬁt has been observed with these checkpoint inhibitors in 
heavily pre-treated patients with mRCC. Immune checkpoint inhibitors under investigation include the 
cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitors, ipilimumab and tremelimumab; the 
programmed cell death protein 1 (PD-1) inhibitors, nivolumab (OPDIVO which is US Food and Drug 
Administration [FDA], approved), pembrolizumab, and pidilizumab; and the programmed cell death 
protein ligand 1 (PD-L1) inhibitors atezolizumab, durvalumab, and avelumab. This clinical case of the 
complete response to the association of Bevacizumab and IFN after a nephrectomy is probably a proof 
of immuno-sensitivity of renal cell carcinoma.  
Conclusion  
Bevacizumab associated to IFN has an FDA-approved option for ﬁrst-line therapy in metastatic RCC. 
But this association is not refunded because of its low beneﬁt. Additionally, cytoreductive 
nephrectomy is usually indicated before starting the systemic treatment in patients with metastatic 
disease.  
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